[
  {
    "id": "22c1b8c40a6df80a251ab937c046c330",
    "title": "Saol Therapeutics Receives Complete Response Letter from FDA for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD) - PR Newswire",
    "link": "https://news.google.com/rss/articles/CBMipgJBVV95cUxOZVhnWmVHcXRYbDZOckpfajZnZHk1cWhDVFlPdmlDOUNyY3I0X0ptSG1iazNEdFc3N0lfYTBmVHVBazIwazAzOXlkaVRDdWdkaWpvQmVqVmtHSnN3dVk4TzRhX2tqMjNJc05mSkRNY3ctNmMyMFVtNmpwVDVLV21VMHhyVm5LZlVISThzWkxXNjVIWW4xT1hPX0Q4VXBtc0l3WkxHREtibkFTUDh6ek9ITGhTRnVlZXFVTTh1dzZHRTBnWU9pSHBjX0lieEVxRFlpLVdxTEFPRndaSU9JODZpeS1lY0RkTU9VUl9oUXFneG41MmRESnZ3UkF4Q25EOE1lb1FaWXVxbXlUOGhNaFNSNVVDRXhQcUhDWUczQ1hXVTZHb2g4akE?oc=5",
    "date": "2025-09-08T15:36:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Saol Therapeutics Receives Complete Response Letter from FDA for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD)  PR Newswire",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "180f384e3f2b65bd8112cae375fbd77b",
    "title": "Saol Therapeutics gets FDA Complete Response Letter for SL1009 (DCA) in treating PDCD - MarketScreener",
    "link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOT18zTFJTSWhCaUFzNzVRMm9EY0xnNXIxQ3E4cWpSaDlPSUdZN1hPS0JCVkhUQjlFakdMNTBwU0pIdVp3eGZQblo1TldsY0djX0h4bFlwVnQwZXBzUDVLaDNUVVFjelkxMEFiZzV4bXp0cmwzTWxHSUl0MG9ueUtGRUNXUnIxQjB1YXFDdnROOWtLNzRoZHZIWG5QdHlWUk1IMzRlR1dTQ054dl9zVlRoZWJQR0pOcE9aTFI0WmI4Q19VZTVOdm9jdEVKZHFGeE1MekE?oc=5",
    "date": "2025-09-08T13:09:45.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Saol Therapeutics gets FDA Complete Response Letter for SL1009 (DCA) in treating PDCD  MarketScreener",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "9b17d4cf6dcae59d9f03d40f8b76dcea",
    "title": "Lexicon Pharmaceuticals Submits Additional Clinical Data for Zynquista NDA Resubmission Following FDA Complete Response Letter - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxPSTkzMGVqS2FrOVlsZzMzRkRPZWlBckEtSEFIYXVRTVM5Vlp2bUw5aXJXeExoaE1IdnFrUFBEa0tnRDhWRzBrZ0FUbHdwVzFHREo0WF85QjFrbXFDOTFsZGlDMjlRVWs4b0VKV0MwYlhMZkE0V04wc1FDaTdwV0syb1JhYV9sVWpfeWNYY3pfMVVQTHZES1V0bVBpNkFIejA1Wk9HSEY3OUFSUG1IOU9uSDBQb3Vudzl1OHcySWxDem1OTWNJSzFnUEQ2NW5Dd3lvcUJiRTZ4aGR4X3Y3WGo2Mzk5S2tHRWplNU1VV0Y1YWo?oc=5",
    "date": "2025-09-08T12:43:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Lexicon Pharmaceuticals Submits Additional Clinical Data for Zynquista NDA Resubmission Following FDA Complete Response Letter  Quiver Quantitative",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "1efe84c24ba9b40313c489166632e9dc",
    "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
    "date": "2025-09-05T18:56:15.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "b5d5124ad1ae88d3cf772d8bc56a1b75",
    "title": "FDA to publish CRLs in real time; PEPFAR to distribute Gilead’s Yeztugo",
    "link": "https://www.biopharmadive.com/news/fda-complete-response-letters-gilead-pepfar-yeztugo-ac-immune-layoffs/759306/",
    "date": "2025-09-05T15:15:00.000Z",
    "dateFormatted": "05/09/2025",
    "source": "BioPharma Dive",
    "sourceCategory": "trade",
    "summary": "The FDA also unveiled a batch of 89 previously unpublished complete response letters, including rejection notices to Capricor and Replimune.",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "ce621b702e0fbb92ab79029e0ee88645",
    "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
    "date": "2025-09-05T02:37:30.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "2032f6b598bb73e05afe5db5812cc7d4",
    "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
    "date": "2025-09-05T00:09:00.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "6715aab4ece64c16ffe90052628a7eb3",
    "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
    "date": "2025-09-04T16:10:06.000Z",
    "dateFormatted": "04/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "a9cee9fbf59e8315be5e164d0a904bde",
    "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
    "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
    "date": "2025-09-04T15:41:34.000Z",
    "dateFormatted": "04/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "b41d073e41b176d8d4fb1b6831dab8cf",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89",
    "date": "2025-09-04T13:23:32.000Z",
    "dateFormatted": "04/09/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 1
  },
  {
    "id": "bf24062058fd7f5f23bffcc7ef274db1",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNVFdoVlBOSnBCeWZqcUs5by1MMXJwU29qMUlEelRwRFZXYk0yUUlrQmpPSmUtb0ZkNVU0SlRHeVk0bjNjbDRibVNKeTRyX3NmMU41UjREQ1NwQ1N4MC04WXBTRDZwelAydml6Q0RPV2hkME5paWxEWXlFOVR1dXBxWGlZRG9HMVVFeXJkT0NaOUdXSkNjQW90OTRVemszYm9BcUlsNmNXX01xRXBJZzhyX0dnNEltRkVtUnFoakxrSFdWS20yMFZvVzJyOG1BUTM3bE5QMEcyVVFnOU1NenM4Uw?oc=5",
    "date": "2025-09-04T04:00:00.000Z",
    "dateFormatted": "04/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89  fda.gov",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "3099851011690c5f5dd97edd3ae8a932",
    "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
    "date": "2025-09-02T12:44:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "96d89fbceece0dde6a11a953379b43f6",
    "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "c2b847fa25fd227b2fe99c77741bad2c",
    "title": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC - Urology Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTENaRm5KN0ZXT2V2dUpYWWRiTU5RSDA1R18xcU5IcWplcms4b0VxYU8zTllCQUJJU2RJZDNCWGxGS0VUZXhPMGEwTmV0M2gxbXRBMHZFTHlJVC1iZzhTWXlkYnVySWJtZUI1aVN5eFp1R0JGOVhFRlkxcTFIaTU1LUJfaUY2VUxPWXJkd3RqYWVXdk10U3Uya2lvYnUwNWRvTVh6Wm03QQ?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC  Urology Times",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "3b3a7591367e3c0cdca084ffba1a19f4",
    "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "5f6d5a74a1a57e86e6e373d2c4d31943",
    "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "84d1ae52e5ada7cdf25dc5ec5337c2b0",
    "title": "FDA received complete response letter from FDA for Columvi in DLBCL - PPF Group",
    "link": "https://news.google.com/rss/articles/CBMioAJBVV95cUxNWXhMcURoaGVLOVlfV2lBN01uc2VuRTU1TVlxcE1kdkFQekNETjRFRW83M3huT3lIRFMxY0xCOWtCVzFKd0JSczc2TV94bXN5TlVWWjVKQm5nMkUzRWhwdDZPYWdrZ3l0d2JUYWFSQXNCeE44aTNQTGVBRG5vVWhvRExPUnhUMzBibUFJTFIyWGFjOGpGblR0Y0hHUy1oTDQ3RjdTY29jS0VzX1hzWF9QYktyaHlPR2RmMGVCX0xGSVRMNC1iUjlacnRlZndmeG5qVVl6ZFdMRkRBUGhpd3BFbjhhWVZWQlRoNFloYWYyQ25jTUZRZXhkSGFzY0ljODVxbjBCZHhKN2pCSmloR3oxSzdxRXJCbGNlaXVwOGVlNnU?oc=5",
    "date": "2025-08-27T22:51:27.000Z",
    "dateFormatted": "27/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA received complete response letter from FDA for Columvi in DLBCL  PPF Group",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "ea485f737d063e77d095fc3147314577",
    "title": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHMyWmRFQ0VxOUE2VW9zdkg3MzQ1S0NnWldQNTcxeV9UM3RERjNKNFZSdzFFZnF2OHRHTThPWDN5cm40Nk1STTNoTkZWUTNwc1BNbkRDTnRaT0F0VzJWUVVTbjMtWEtKanVjRnkwNHZ2ZVM2S1BpUFZhS3FjNnAyVElJRXozdkxGanp4ZHdOdmxQS0FjbEVSaFVvVnk3eUJiYzlURGZEbFh4WW5p?oc=5",
    "date": "2025-08-21T07:00:00.000Z",
    "dateFormatted": "21/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro  geneonline.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "04a03762b4adef7b83a038f1d36ec93d",
    "title": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdEhEZjBoaVlxbHNHc0drWWxWdzd6cVBIdkhNd2FYeXpyZ0NISnI5Y2VVT3FqSGlVOUdIZ3Rqc0hxeUhja1UwSk9QeEFiZjJkbVB3ZlluaVFyMEkzendEZC10UWZNLWpGTzFkYXpKSmxDMnE0cUdtV05XSzJCRXZvWFEzVUxKUVJIemFJVnNNUHhOX0NINmxiRnFGX1Y2ckF5dmVsX1phVmphbkFtbmU2MW5LTURFbkdVMzh5UmhXYTZLZHR6VG04UUZkSlhwUUR3REZuU29EMGR2RnhMMlRNX2tlT2FBNDVvS292cnBNUlk2ZWIy?oc=5",
    "date": "2025-08-20T18:08:52.000Z",
    "dateFormatted": "20/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia  geneonline.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "067013309eabf80122f628fa63870ffb",
    "title": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen - Curetoday",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPNi0yMDRsekFtZmMwZFB3cjdOekF6WGxiUnJPWnBPMU5RQVBkaVZCVlh3SlJKSGgtaXdTcjZraTNJSVpzMXBNUDR5aHJZUlF4YzNQUk85VVpsRFRKNzZmOTFKNWcwc21oeGQ1dkY5UDBpZWdpaUdLbFhBdkdIVkF0VUdfZXd5ek5PQklmM2dQU1Rtb2hQQUE?oc=5",
    "date": "2025-08-20T07:00:00.000Z",
    "dateFormatted": "20/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen  Curetoday",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "fc3c76470f16125af17afc4b53b60382",
    "title": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA - Contract Pharma",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPN1Zpanp6WWlzNWUzRnl4NXRpOFdWWVRRRE1laGZZdGRJbDVzWFZ6Q0N5T1F0MkRQbEgwc1FmNzB3X1Jqc1lTa3VEMm1vMExiRUFtNENZRUNabWR4anQzMWJGcXZHcXV5NUI5QjZBQmxINnQxMnJlN0JOTEh2aXJpUGVqczFPTU01N1QtUFdBNjhzNHN1VVlFOTZ0WjdtcUlTSWxBWA?oc=5",
    "date": "2025-08-19T13:56:19.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA  Contract Pharma",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "248fd8dcfd712c13bcd669ba6a3d7460",
    "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
    "date": "2025-08-19T07:00:00.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "ff40c860894a9d81d2399ddd79ba5efa",
    "title": "PTC Therapeutics Receives FDA Complete Response Letter - MSN",
    "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZmI0WlRSMDNhNURtOWxSbkJrLVY3UFFNODhiTmxEc3NxeTB6VEhVSURFWEh5VUxCTFZKLUJsT2lEZjVlcEhlM3Rpb2htdjdLcnVoLURIcHhxaDcxVFI2YVRtOWNET0Q0OVVEU3ZtQkZVaGpTQWNuUXR2anotbHdpY3ZGTkZzU2V3OGQ2bFoxVDdtaG5CWDgyRnhHRXNkWXJqY2lpVzlKeEc?oc=5",
    "date": "2025-08-19T07:00:00.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "PTC Therapeutics Receives FDA Complete Response Letter  MSN",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "348cdcbb4208eeda8b3cc31ede9859fa",
    "title": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment - Neurology live",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSEJkaW1DYnZ3THRNTWdpc2hNMFh6dXNPUHdFUXoyRjlwWnRQVzZybXNGMmtDOHdsVnA1M0NIU0UxVUlGQTYxLWVIM0FmcGlFMWY2VFlXMTZINVNfRmppWjMxRlY1VWVXUE1GVjJubTRZTEdrOE1GZXNqV1QwbEZLcFBNYTFYTVNRTno5UUhibG04QW5LUUNuTFZTdFcxTERoYWo3Y2tLQ3lvV1ZkS0EzcUY4Ulp5LXd5V0E?oc=5",
    "date": "2025-07-30T07:00:00.000Z",
    "dateFormatted": "30/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment  Neurology live",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "0196908febbc8ca91cad47cc5812de7c",
    "title": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeUpKUXVENG1XWnEtZHRPR0ttTkdJOUNidUMwMUJvY3pTY3ctS1VNeUd6Wi1TaS1KVks5REdYTERpcUxmTndpVnk5VGtfd2pqUGZvSUFvT2JJTGxOWHpKczh2LUl5ai1NSG9IV1VsLVg0aHlwRThsOXpVZUFiNlBtVVdRUjJ0Skk0eTRkU0g4d3FGQVJRSnFSLUV4OTVxRDVHOHc?oc=5",
    "date": "2025-07-22T07:00:00.000Z",
    "dateFormatted": "22/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma  CancerNetwork",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "2f04a34c67581599b700660c3cafee37",
    "title": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOTHUxdXliYVhkdDUzQTJtZFBuN3oxQzlub3FHaVVtclNlOHQtTHNSdWNPYzhiWXdST2V1VnlMSlBmLVdvSFEwLUsxMXk4WTgzUkE3N1ZSOUp6Mk1tTnZCb0tLY1RITmRoY3YzdS1PVkdBVW5nYkJFV1dDdVdFNzFhWFhSX2QzQ3gxa21vMEhSYWJfZWREMFZRckN2ZFJaTmNGZ01jNHhXc0NIaEZuM0RieV80dnFpZmFNM2J5MHRLODdJYnBJMi1EeDQ5aWs2ZUJ4WW80bkxUaw?oc=5",
    "date": "2025-07-22T07:00:00.000Z",
    "dateFormatted": "22/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment  geneonline.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "db259fb9a119778cd0c3efcf37dbf221",
    "title": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZXlhSFNScVd3dFNhSDBQemMyMVpNUExDeXRYNDlYeFNhZ1F5RGlFcmhPbURGX05tZUhkNFpNdVVrYzRQWnpFS0pyZFFabnNZUXRjNzdRazBZdmV4RS1ZLVFUNFVlbjI1ZVZTQ1RZTzJ3NU9hbzZJZ1dDZ1lremdyUENyU2tlRkZwSVNsTHJweWlXLWtXRVZjRVNSYnNMVW1xTUFMZXlHZllZVHFWR3c4MkptbFpjTGM?oc=5",
    "date": "2025-07-21T07:00:00.000Z",
    "dateFormatted": "21/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy  Targeted Oncology",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "3b09c287bff7b399c1ba6eb598a89343",
    "title": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOEp5QUp6MFBYajNKQlptc0lpeWc2MGZYb3E1ckR5MW1GUUhDS2w0TWhWdjFpeVpUbWh3THZPRWJaeDZQWFloem5sZnJUaHh1cTFtWDd4dnJBb2h3MTdWTDBHVnd6cjdtREt0MGFiWjJWcEF5dldvajV5ZlFyQjRKRDBxYTNtUGg3ZHljdnBhdEo5UmFibE1CcVFnNFVBaWhnaHc?oc=5",
    "date": "2025-07-18T07:00:00.000Z",
    "dateFormatted": "18/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL  Pharmacy Times",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "ca09c1469fb105d83ef94bb190fce674",
    "title": "Ultragenyx receives complete response letter for UX111 BLA - Pharmaceutical Technology",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVUszb2g2NjVsalpmZlZPTmpybFNBVHBiWFRvNHY3NVJhRm1LaTNiMkdjTklkMndSWmFUMDFFTkt6ZXFNYU1ZYkM5QzZEa2NCN1g0MzlmLVRaN1VYdVdCbkdOVzlJRlBXYUVjM3U5Yk5WbEFVVl9KV0NZZjkwSkpMQWc4UDVkekJDUmRTNVFqWllYTHM?oc=5",
    "date": "2025-07-14T07:00:00.000Z",
    "dateFormatted": "14/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx receives complete response letter for UX111 BLA  Pharmaceutical Technology",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "1f097fb48fdc496b390c6e58eb3b95e4",
    "title": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNk02ME02b1NUMHltNGRvNHl4eTRVcTBsZzVVc1NXVEFMX1RCN1lZczg4T2NDNm13VmxWWGpUdFhGNk1rSmlMNS1NcHkxZEREdk5sZ1lwcU9hV2NhQTg4RUo0WGxTLWdZYk1zdm1Jb1FGS0hxRXB1Vi1Kd3ZjVzhxeWQtVlFxeHliZ1FjOTZPVi16eXdFMzJlQmRMRjVpNjhNc0l1aC03T1hPbE43UjBhejRrQXRRNnFITF84TXpEX2haMDJ0?oc=5",
    "date": "2025-07-14T07:00:00.000Z",
    "dateFormatted": "14/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter  Seeking Alpha",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "6474d01b5fb92c06ce99c5e0765cf3b7",
    "title": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNT0w3NDFEdGlZTG51M1VtMnZhS21xSGlCNjA5U0dTeTZmS01iUDFHbGNvR3R4Szl2LThwcE1ETjVtTmFOUFQ5ZzFZQUdwa3ZSWEZGR2s5YnBOZzVkZHpaNVQ5MHlVRndUaHlCZXRjVXd4cnY0UmhxbVBycjVSX19oaVNKdnI5UmlLQWZwSUllLVBqQ3RvQTNHN3JCUzdxT3M5S0E0X2ZWVEJWelBZR3Fyek9XNUZhcGc?oc=5",
    "date": "2025-07-14T07:00:00.000Z",
    "dateFormatted": "14/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application  geneonline.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "810c7eae494949f8f65fd8a6d99d11ba",
    "title": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy - FirstWord Pharma",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBalJyWmlNZjQzUWxrRFpsVm9XTGhwMlFBWVd6QUw3S280U1JWX0NQbWZVTEEyVVhvVHF6VHBlenJoOTFHTlB2UnhNOHZqSW9Cck5v?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy  FirstWord Pharma",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "ba6a51a98357b91c0bd605c6412ee852",
    "title": "FDA issues complete response letter for Ultragenyx gene therapy application - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdS1qUDhaaDlELTdWRElCUG1mT0RlNDVLc1ZmSndvNEVMSlk2ZjVoSjk0cENpTV9lRU1SQ1V5SzMwckxLck51N2VkQ3ZkSUFEeTNESjZjLUREOTVaV3VHa3VDOWNfS0VxaXpWTk1pRUdQaWZkdi1BdlRORGRaaWdXeExBWmk5am4xUXBpWkFDNWg5bmZmUTUxeEhMSE1zZUVIS29YWmV2VHB3VnRvOW51WVctODF2dW5iMVBxdzFPcnpyZGUtNk1aSktEYw?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA issues complete response letter for Ultragenyx gene therapy application  Investing.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "b9caa5b4896643d7d3b501402baaef4d",
    "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "1b77986b4537acfac75ec2d9873a14fe",
    "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "e7ef225d5738607488f6e8a422d14c4b",
    "title": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdV90QmVuOUpBcXoyc01JNWFHYXVRdFktRDBHNndBM09EbmlFOUtrdy1qR1BQSHp2MnN3MUpiNHozZk4yNWphRzFlcjJPSDJXMkd1X1p3QzFsRHp2SzlJMkltbm5zMERJRjcwVlpHSDh4VTRSYkRNTEU5dm0yMUwyWjV1WGNsNFRrcUtUenhiU0Y0THpLMS1PbEphcC1GSnlzLW1sUmpUcGxFTV9qY1ZkdzAyS1QxM2dSRFkyVl9SMFNtWHM?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy  Investing.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "a16ee55b817704317942e0e0e273bfde",
    "title": "Capricor: Maintaining Hold Rating In Light Of Deramiocel Complete Response Letter (CAPR) - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPcGUwcUhXSVBsQi0zRXVkbms3TjBrdm9TcEZTTWFVSEwtVU53TjVQRGd0cHVGNEZYUS1iNTRiV1ZuU0hXb1gwNTd4Q2ZOUXBoQjAzU3J0MlhCMVhCTk16eHlYU0F6RVdBMzlZQzB0T2RYTXhGWjBLaTR1N1RNcnpaUGQ0Qkc0VUtfSW1rSmtObEo1ZVBoeldUcnBLc1VMQ2VqOHNiMm85OGVxMnJNX1EtdWJlMUZZYkRJYm5FeVR3?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Capricor: Maintaining Hold Rating In Light Of Deramiocel Complete Response Letter (CAPR)  Seeking Alpha",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "02f7a9a23e06335f66aebd8d161a0f6a",
    "title": "Just how radical is the FDA's complete response letter move? - pharmaphorum",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOQlpqYUp3SmJZY2JTam1VUGhNdHh3YWFjdXN3OWYxYkhDbnNLWVJqUWoySHpqWnlwdnRlNXJYWGwwclBwOW9NdllJX1c0RWRjaHpleDVpbHlMVkFkM0NxUzA4N0wwU0FUQXNBMWpIWnpWMVV1OUl2U1liY3luODUzQzRUcG9NNmxs?oc=5",
    "date": "2025-07-10T07:00:00.000Z",
    "dateFormatted": "10/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Just how radical is the FDA's complete response letter move?  pharmaphorum",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "03b77a33feacaf843b77ca45036f7b1f",
    "title": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMWtoZlFGel9acHZOWlQyMm9sS3FhYUpjd240RVZRTGY3WmZkNENTZndFSGVfSUx2UWRBcHJybzlyZWZQTHMxZmNRNWZaWTVJeXBRYmhnM3gxTVA2bFBLY1RRLWNtRFF6dTJjdHpsajh4UXE0aU9PeGtjV1Fsclc1QUNTRWNZZG4zRjVzQWFxd1BhQjhWN1pwODNicXY1VERZYWZTMFBheTBuY2FDMVlXZjFwU0dTSnI4RGd5dllFbGZEYjczemlyRXdKMHBRTVotQXVB?oc=5",
    "date": "2025-07-02T07:00:00.000Z",
    "dateFormatted": "02/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia  Pharmacy Times",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "959bc0281b82233af43d450bb24fbbb8",
    "title": "Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbWJhY2x1N1FEYVBlMktadHBUWE1mSUpMdVRQa21zWVZ6dG5oZ0t1c1ZhYktWZHdiOTEwTzdGQUNPVFhqT3V4UUhrS1huU0M2czZNOFBoNUlWb0x5ZFBzVFJVUkpOM3lZUDRwMHNydmJSZk1kRzBiWFVBcHZ4OGdvaDloWVJ1bXZic2RjY1Zvclh1MUhZc2p2NjVMVDNET2hPajBoU3lXX3FBTk95MVJCQnQ4dENTaU9JMUFGWjJxbUEwc2xWQWc?oc=5",
    "date": "2025-07-01T07:00:00.000Z",
    "dateFormatted": "01/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Unicycive stock falls as FDA plans complete response letter for OLC  Investing.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "edee4d0068bbd758dc7932c1277548d4",
    "title": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHNsMWNuaTNURmo2SVJ0MkZwczNsNkREY2g1bG1XRnRZREUyTlFreVZNYXdlNkJYMjZBV3FwQ2twZmQtOHRPUzNvR2tRNVpFbWxVT01paU9VcGFSQjhMblpFZzg3U25iRlNIZGxaQXFVUTBYb1R6dTVrbzYxamZtUERSazFfS2xIY0g5dGR5ekI0RndTM0lyN3pPc2pnTGhPaklOUVJpZ0FfbW04eUNwVW1kMDAxSmh6QnhRYXlkS18?oc=5",
    "date": "2025-06-30T07:00:00.000Z",
    "dateFormatted": "30/06/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect  Fierce Pharma",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "41b1b159da63694c560554de5ccece94",
    "title": "FDA issues complete response letter for Unicycive’s kidney drug - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNek9uUkVPNnlxOWU1Ykdia3RQaDFUTjVXc1FUeHYwMHBGNENSUVlhR3RZUEFoLWhRZlRzUHVwMVowOV9MV1V2Z3UzWHVqaUhDdkx3bXBWTjhDQkRPb0hibllsVnV4MDJVeC1aWkp0eW9rNVQwcVd5UEtUR1ZPSlh2aW5wLW5JR1hOaER5NnMxZ3JtMllGcmZZaHBhTUhLZ0hET1gycEw2WWhfbXVFVkxURXJqVEx3VXBRS2cw?oc=5",
    "date": "2025-06-30T07:00:00.000Z",
    "dateFormatted": "30/06/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA issues complete response letter for Unicycive’s kidney drug  Investing.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "5f1a8f5ee450b6e4ba4519426598f7ca",
    "title": "Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHV4ZmJtTkl4X21OZVFyU0t4VkpBVTFmMWZVS3JSd3BBa1Y3Zzk1OHo3NFNwNldHUjBSU1BoRlhnZWpRWFQ0Y3lDRlYyWk1QVUhlaHZaX0tXbFNyMnFxeTZKMmw2LTBfalF2ZFRQRmdMd19vMklBRkZiQkFjTWZBTGZCbWcta21MNGIzVUpOOXFPT3FzenNrMUJabTNfS3RmWEZ3MzVR?oc=5",
    "date": "2025-06-16T07:00:00.000Z",
    "dateFormatted": "16/06/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Milestone submits response to FDA Complete Response Letter over Cardamyst  Seeking Alpha",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "40e358a22c6974a052cb45cf9adb130a",
    "title": "TLX101-CDx Given Complete Response Letter for Glioma Imaging - Oncology Nursing News",
    "link": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxQVmIyemZUbEpPZmx3cGNyNTg1blVBQ1hUNEN1R0JXRDlST05aNzVuTTU3ZXJHbW5LREFmdnU0c3pad0lmN0pycnY5ZW0yU2lBLWgtY0R1aHpnbkNLQktHTlp3eW5GSkoxWDdfcm1fcmMxWnVYcGFRdGh0c29kWWNrMWw1NENHS0RKMVFsdTIwV2JmU0NWTUJ0by1QWXp1Qmd6ZmhWYlducDBaYTlkX19UcU41NzN4LUo2MWpKb0FpMUhNTU40aGczVTJOZ2dhZm1GT1VldExRNkhLalMxSk42TXF4WFFFRVA4S0FqZw?oc=5",
    "date": "2025-05-06T07:00:00.000Z",
    "dateFormatted": "06/05/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "TLX101-CDx Given Complete Response Letter for Glioma Imaging  Oncology Nursing News",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "d8b10d7aedf0b9ba0ceaa9e49256b074",
    "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
    "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
    "date": "2025-04-03T07:00:00.000Z",
    "dateFormatted": "03/04/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "3f39e67a385eef1ded05bd6ef05e350f",
    "title": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNLTlmaDFOclA3OUhtMkdzQjBtQXk3S1JKbl93VzJBM3R2bGRDRUpWQWQxQnZhY05qS0pOTXhNcnJpZE5jTVJnbmlvR1pGa1EweWc2aFkxTldEUEQ2RDZOaTZsS184ZUYxVHN0YmNEOXZlUUt1N3hqNl9VVjJNQ3BKZ19HQkxYbFBRNWdMYnZ1aWJVdlJxb2RweTBfendMM2NQU2I4NVd0MUo1M21Kc3FqS1oyVWwxWE5pZVVzVHVuZUk2dHJiSmhVcGRicDMyMlNVRVE5b1YyRmRIT3BXRzBCOEZDRzA4TWtFNGc?oc=5",
    "date": "2025-04-03T07:00:00.000Z",
    "dateFormatted": "03/04/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis  Pharmacy Times",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "2308fbf84d17fbcca8d0cbe43cf1633a",
    "title": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPRWpwOHNXTXU1SnYwOElkLXphQ010LWtqUWFva2Z0bjVLS1p0d0Z1VGpLRnlaUTVFRDZpQWlBME9xZURmaWlGNWdfMTZiMl9KN3FJbTRlbEQzODhXWHMyRnd5cGQ4d2E1N3p4WVQ0a05FQzRES0pZUGtjanpyZDhLMVNSUTZ6V2lQQTZxNkphOEtGMkdlb2Q4?oc=5",
    "date": "2025-01-16T08:00:00.000Z",
    "dateFormatted": "16/01/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD  Targeted Oncology",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "4c0f25daa5a229aa14a042a72e05b568",
    "title": "Complete Response Letter, Warning Letter and Shareholder Lawsuit Follow FDA Data Integrity Findings - JD Supra",
    "link": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQUGhhVWRtUDA3TEtVa0p6VElTMGE1eXNMcl9mMG1fY3FsdU1xSFdIODBGNWdMVlUtekUxUVFDbFVtZmpxVTF5WVdEblE0MTI0aFllWHJ2ZEM0UkhRcWNYRUdwbTlibUlJUzdPMmEwOUFRdWlTVXZGc2VMa0tvS3NaRXhRRHM4SGQwZGc?oc=5",
    "date": "2025-01-15T08:00:00.000Z",
    "dateFormatted": "15/01/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Complete Response Letter, Warning Letter and Shareholder Lawsuit Follow FDA Data Integrity Findings  JD Supra",
    "company": "TBD",
    "types": [
      "warning_letter",
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "bf9e8d6d9fef82689e3e382b4dc18dfb",
    "title": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWWFneWJYcGkyU3JDOTJtd0s0RERBdGVTenhmRnc3ZEZyWk1jd2V1akNTLU5Ka190WEtVd1NQdHgzTVVxR3NjeVpZWnl0SmtOZ2dkcnhpZHhIMmRNdTlDME1aekJmQkk5SVB4ZE8wclBHd2YzUm5FalY5eDFhamhMY05JUDR4NE8yNkI4enVMZFZTczIxVWhUdlRUMDBqRnFaaFhmdDdXUQ?oc=5",
    "date": "2024-12-21T08:00:00.000Z",
    "dateFormatted": "21/12/2024",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog  Pharmacy Times",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "99f572e7e794bbbdf39dee7c547ef278",
    "title": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC - OncLive",
    "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcDhYRTAzSEdTSzI5OGJ5UGFnWGxWMERJME9Vam1vUTdmYkZtNnJua082QVJaQnB1UEEzbWVDVVpaMGJPaWZrZ1o4YnE0aFVWUzBaai1rVGVwLUFQbWFkRkRpaUd6RTA0aG9GUXRnd1NJQlVYSFRrdEFlSVRXdjdEUUpDSzdpZHplT2ljdGlkOXBjNDdndi1tbk1XOWNscWhSUXpwXy1rZkpuRXFMUmQw?oc=5",
    "date": "2024-12-17T08:00:00.000Z",
    "dateFormatted": "17/12/2024",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC  OncLive",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  }
]